$5.77
2.20% yesterday
Nasdaq, Aug 11, 10:01 pm CET
ISIN
US30052C1071
Symbol
EOLS

Evolus, Inc. Stock News

Neutral
Business Wire
4 days ago
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in August of an aggregate of 12,731 restricted stock units (RSUs) of the company's common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committe...
Neutral
The Motley Fool
6 days ago
Evolus (EOLS) Q2 Revenue Rises 4%
Neutral
Seeking Alpha
6 days ago
Evolus, Inc. (NASDAQ:EOLS ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants David Moatazedi - President, CEO & Director Nareg Sagherian - Head of Global Investor Relations & Corporate Communications Rui Avelar - Chief Medical Officer and Head of Research & Development Conference Call Participants Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Rese...
Neutral
Business Wire
7 days ago
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2025. “U.S. toxin demand softened in the second quarter, driven by reduced patient demand due to a sharp decrease in consumer sentiment which resulted in a...
Neutral
Business Wire
12 days ago
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of a landmark independent study in JAMA Dermatology directly comparing four leading botulinum toxin type A products for the treatment of glabellar lines: Jeuveau® (prabotulinumtoxinA-xvfs), Botox® (o...
Neutral
Business Wire
21 days ago
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these resul...
Neutral
Seeking Alpha
22 days ago
I maintain my Buy rating on Evolus, confident in management's guidance and optimistic about Q2 earnings exceeding Wall Street expectations. Evolus is demonstrating strong market share gains, successful new product launches, and reaffirmed 2025 revenue guidance despite recent share price volatility. Key risks include exposure to potential US tariffs, reliance on overseas manufacturers, and compe...
Neutral
Business Wire
about one month ago
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July of an aggregate of 12,385 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committee ...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today